85% of Clinical Drug Trials Face Delays. What’s the True Cost?

 

Clinical trials can save lives and provide new ways to treat disease. The industry estimates that 85% of all clinical trials face delays due to patient enrollment. Understanding that challenge and finding ways to minimize it is the pursuit of Jeeva Informatics. The company’s founder and CEO, Dr. Harsha Rajasimha, joined Kevin Stevenson on I Don’t Care to discuss the issue.

Dr. Rajasimha has a long history of clinical research experience, working as a data scientist and software engineer. After several personal tragedies, he wanted to apply his knowledge to helping clinical research trials overcome logistical burdens to bring new treatments to market faster.

“The biggest barrier in clinical trials is delays in the timeline associated with patient recruitment. Traditionally, those enrollees must be within 50 miles of the lab,” Dr. Rajasimha explained. That narrows down access considerably. “Only 1.2% of cancer patients in the U.S. are in a clinical trial.”

The other challenge is the logistics. Patients must travel to sites for treatment or simply just exchanges with physicians. “It’s a travel burden for patients and their caregivers,” Dr. Rajasimha noted.

To change the clinical trial ecosystem, Dr. Rajasimha said that the paradigm of the four walls of the lab must evolve. “Clinical trials have been slow to adopt digital channels, but the pandemic forced this.”

By digitizing and automating repetitive manual tasks, the burden of participation shrinks for the patient. “The pandemic showed that there is a demand for flexibility in decentralizing clinical trials. With the right tools, this is possible,” Dr. Rajasimha explained.

By leveraging technology, clinical trial producers can maximize diversity, equity, and inclusion. With more communication and interaction, patients in trials are also more likely to adhere to medication instructions and be more trusting of the process

More Like This Story:

Is the FDA’s Accelerated Approval of Molnupiravir Setting a Pharmaceutical Standard?

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

Follow us on social media for the latest updates in B2B!

Image

Latest

automation
Revolutionizing Revenue Cycle Management: The Power of AI & Automation
July 7, 2025

Amid a rapidly evolving tech landscape, decision-makers need to navigate new AI-driven solutions addressing industry-specific hurdles. This session, recorded at the HFMA 2025 show, sheds light on how leaders are using pioneering automation technologies to stay competitive and efficient.

Read More
Portable AV system
AV Anywhere: Portable AV Systems Are Now Essential for Mission-Critical Response in Unpredictable, Connectivity-Challenged Environments
July 7, 2025

In crisis scenarios, portable AV systems must perform under pressure because failure is not an option. As Keysight Technologies notes, the evolution of mission-critical communications now depends on low-latency, mobile-ready platforms that can operate reliably in unstable, infrastructure-poor conditions, making portable AV systems essential for real-time response and public safety operations. These are the…

Read More
future of marketing
Vibes and the Future of Marketing with Adbloom Founder and CEO Andrew Abony
July 7, 2025

Affiliate marketing is shedding its outdated reputation and entering a new era—one centered on authenticity, emotional resonance, and genuine human connection. As the future of marketing becomes increasingly relationship-driven, this shift is impossible to ignore. In fact, during the 2024 U.S. Cyber Monday, influencers and affiliate marketers were responsible for driving around 20% of…

Read More
brand identity
The Branding Balancing Act: Reinvent Without Losing Your Brand Identity
July 7, 2025

The recent resurrection of the Pac-12—reborn with new members and a possible rebrand—raises critical questions about what keeps a brand relevant in the face of disruption. According to Yahoo Sports, the rebuilt conference has signed a five-year media deal with CBS despite fielding just two original members, underscoring how legacy names must evolve to maintain…

Read More